Closed · RFA-HD-22-010 · CFDA 93.865 · Discretionary

Technologies to Advance Precision Medicine for Reproductive Health and Infertility (R43, R44 Clinical Trial Optional)

Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.

Varies
Award range
Closed
Status
July 29, 2021
Close date
-
Expected awards

The verdict

Technologies to Advance Precision Medicine for Reproductive Health and Infertility (R43, R44 Clinical Trial Optional) is a closed discretionary listing from National Institutes of Health that offered Varies by applicant. Future funding cycles may be published under the same CFDA number.

Varies
award range
Closed
application status
93.865
CFDA program

Opportunity snapshot. This Grants.gov announcement - Technologies to Advance Precision Medicine for Reproductive Health and Infertility (R43, R44 Clinical Trial Optional) - is cataloged under number RFA-HD-22-010 and tied to CFDA assistance listing 93.865, posted by National Institutes of Health. Grants.gov currently shows the opportunity as closed, first posted on March 31, 2021. The funding category is Discretionary, delivered as a grant.

Award economics. The award range on file is Varies by applicant. The agency has projected $1.5 million in total estimated funding for this announcement. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.

Deadline and action path. This opportunity closed on July 29, 2021. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.

Award Range

Varies by applicant

Close Date

July 29, 2021

Posted

March 31, 2021

Est. Total Funding

$1,500,000

Instrument

Grant

Description

The purpose of this funding opportunity announcement (FOA) is to encourage the small business community to collaborate with scientists and clinicians in the fields of female and male reproductive medicine, infertility, andrology/urology, and gynecology to develop, adapt and validate discoveries in genomics, epigenomics, metabolomics and biomarkers to the clinical diagnosis and treatment of women and men with infertility, and diseases and disorders that affect fertility. The ultimate goal is to advance the application of precision medicine to reproductive health through the development of new procedures, assays, digital apps, devices or technologies that improve the specificity, accuracy and rapidity of diagnosis and enhance the individualization, safety and convenience of clinical care.

Eligibility

Grants.gov lists this opportunity under eligibility category code 23. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV

Key Dates

Posted March 31, 2021
Close Date July 29, 2021
Archive Date September 3, 2021
Last Updated March 31, 2021

Frequently Asked Questions

What is this grant opportunity?
This is a federal funding opportunity titled "Technologies to Advance Precision Medicine for Reproductive Health and Infertility (R43, R44 Clinical Trial Optional)", offered by National Institutes of Health. It is associated with CFDA program 93.865. The purpose of this funding opportunity announcement (FOA) is to encourage the small business community to collaborate with scientists and clinicians in the fields of female and male reproductive medi...
Is this opportunity still open?
No, this opportunity is closed. It closed on July 29, 2021. Check the parent program page for future funding cycles.
How much funding is available?
The award range for this opportunity is Varies by applicant. Total estimated funding: $1,500,000.
How do I apply?
Applications for federal grant opportunities are typically submitted through Grants.gov. Visit the official listing at grants.gov for application instructions, required documents, and submission deadlines.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants